Mekinist® (trametinib) plus Tafinlar® (dabrafenib) – Expanded indication
August 31, 2023 - The FDA approved Novartis’ Mekinist (trametinib) plus Tafinlar (dabrafenib), for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options.
Top